RxDoctor Payments Data

Richard Monticciolo, MD

Internal Medicine · Rocky Hill, CTNPI 1790747970

Payments from drug & device makers

$2,515in general payments, 2019–2025

Across 113 payments — averaging $22.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$948
  • AbbVie$546
  • Lilly USA, LLC$198
  • Ironwood Pharmaceuticals, Inc$162
  • Exact Sciences$147
  • Pfizer$121
  • plus $393 from 10 others

What the payments were for

  • Food & beverage$2,515100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,515 in reported general payments places this provider in the 85th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$28,793
Medicare patients
63
Services billed
410

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate22$21,577
LinzessLinaclotide23$16,605
FarxigaDapagliflozin Propanediol20$15,821
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$10,349
TrintellixVortioxetine Hydrobromide11$5,085
Omeprazole96$1,344
Metformin Hcl89$894
Levothyroxine Sodium70$784
Atorvastatin Calcium79$740
Glipizide73$709
Escitalopram Oxalate76$622
Nebivolol Hcl20$546
Montelukast Sodium39$521
Divalproex Sodium24$506
Oxybutynin Chloride ErOxybutynin Chloride13$505

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$948$26,17136 claims
AbbVieLinzess$546$16,60523 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$48$78470 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Rocky Hill

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →